What is the recommended management for a patient with confirmed COVID‑19, including isolation, outpatient antiviral therapy for high‑risk adults, and inpatient treatment for moderate to severe disease?

COVID-19 Management

For confirmed COVID-19, isolate patients for at least 5 days from symptom onset, prescribe nirmatrelvir-ritonavir as first-line outpatient antiviral therapy for high-risk adults within 5 days of symptom onset, and treat hospitalized patients with moderate-to-severe disease using systemic corticosteroids (dexamethasone) combined with remdesivir and immunomodulators (tocilizumab or baricitinib) as needed. 1, 2

Isolation Requirements

• Isolate all confirmed COVID-19 patients for a minimum of 5 days from symptom onset 3
• Pre-symptomatic transmission is a key feature of SARS-CoV-2, with viral loads peaking in the first 7 days of illness 2
• Live virus remains detectable in the respiratory tract for up to 9 days 2

Outpatient Antiviral Therapy for High-Risk Adults

First-Line Treatment: Nirmatrelvir-Ritonavir

Prescribe nirmatrelvir-ritonavir combination therapy for symptomatic patients with confirmed mild-to-moderate COVID-19 who are within 5 days of symptom onset and at high risk for progression to severe disease. 1, 4

• This agent increases recovery rates (70.7% vs. 53.6%) and reduces time to recovery 5
• Among those prescribed antivirals, 80% receive nirmatrelvir-ritonavir, and 99% receive it within 7 days of diagnosis 6
• Expect increased adverse events (1.3% vs. 1.0%) but these are generally manageable 5

Second-Line Treatment: Molnupiravir

Consider molnupiravir when nirmatrelvir-ritonavir is contraindicated or unavailable for the same patient population (within 5 days of symptom onset, high-risk). 1, 4

• Molnupiravir probably improves recovery (31.8% vs. 22.6%), reduces time to recovery (9 vs. 15 median days), and reduces persistent symptoms from 3-6 months (8.5% vs. 11.0%) 5
• This agent offers unique long-term benefits not demonstrated with other antivirals 5
• No effect on mortality, hospitalization, or serious adverse events 5

Treatments to Avoid

Do not prescribe ivermectin or sotrovimab for outpatient COVID-19 treatment. 1, 4

• These agents lack evidence of benefit and sotrovimab has reduced activity against current variants 1

High-Risk Populations

High-risk patients include those with:

• Age ≥65 years (particularly ≥75 years) 6
• Multiple comorbidities including chronic obstructive pulmonary disease, heart disease, diabetes, chronic kidney disease, and obesity 7
• Immunocompromised status 7

Critical pitfall: Antivirals are significantly underprescribed among adults ≥65 years, with only 16-23% receiving prescriptions during recent periods despite proven benefits 6. Prescribing rates are lower among rural residents and those with comorbidities, paradoxically affecting those at highest risk 6.

Inpatient Treatment for Moderate-to-Severe Disease

Corticosteroids (Foundation of Therapy)

Administer systemic corticosteroids (dexamethasone) to all hospitalized patients requiring supplemental oxygen. 2, 8

• Dexamethasone reduces inflammation and prevents respiratory failure in critically ill patients 7
• This targets the second phase of COVID-19 characterized by dysfunctional host inflammatory response 2
• Monitor for hyperglycemia, immunosuppression, and delayed viral clearance 7

Antiviral Therapy

Add remdesivir for hospitalized patients requiring oxygen support. 8

• Remdesivir, an adenosine nucleotide analog, inhibits viral RNA polymerase and reduces COVID-19 severity 7
• Most effective when administered during the viral replication phase (first 7-9 days) 2

Immunomodulatory Therapy

Consider tocilizumab, sarilumab, or baricitinib for patients with rapidly increasing oxygen requirements or systemic inflammation. 8

• These agents target cytokine release syndrome and reduce pro-inflammatory cytokines 7
• Tocilizumab and sarilumab are IL-6 inhibitors; baricitinib is a JAK inhibitor 8
• Use when evidence of hyperinflammation exists (elevated IL-6, IL-8, D-dimer, C-reactive protein) 2

Respiratory Support

Implement continuous positive airway pressure (CPAP) and prone positioning for patients with deteriorating respiratory status before considering intubation. 8

• Prone positioning improves oxygenation in patients with acute respiratory distress syndrome 8
• Endotracheal intubation should be performed when non-invasive measures fail 8

Thromboprophylaxis

Prescribe prophylactic anticoagulation for all hospitalized COVID-19 patients to prevent venous thromboembolism. 8

• COVID-19 activates coagulation pathways with increased D-dimer levels 2
• Neutrophil extracellular trap formation contributes to thrombotic risk 2

Disease Severity Assessment

Hospitalized patients requiring risk stratification should be evaluated using:

• Age, sex, number of comorbidities 2
• Respiratory rate, oxygen saturations, Glasgow coma scale 2
• Laboratory markers: urea, C-reactive protein 2

The ISARIC risk prediction tool incorporates these factors to predict mortality risk in hospitalized patients. 2